GLG News by Physicians who Treat Insomnia (US)

Somaxon Pharmaceuticals has submitted a NDA for Silenor for the treatment of insomnia.  The active ingredient is doxepin, which has been available for years.The effect of the drug can be expected to be very modest, side effects unfavorable when compared to Ambien or Lunesta, and with both significant...

It is important to understand that geographic placement of these clinics is important.  I think these clinics will continue to pop up until the industry feels out exactly where the market is.  We are located in the southwest suburbs of Chicago, and there are many of these clinics which are...

The time taken away from seeing patients is expensive.  The physicians do not feel like they are trained well enough in understanding scientific studies and so they may be biased by information provided by the representatives that is not scientific.  They believe that innovations by pharmaceutical...

Increased FDA warnings on ESAs, suchas Epogen, Procrit and Aranesp will provide payers the ability to further restrict these agents.   Restrictions will come in the form of prior authorizations and other utilization management techniques.

It is disappointing that Medicare does not pay for well exams where vaccines like this would be given.  It is unfortunate that in an attempt by medicare to save money, they are probably losing money.  It is at the annual well exam where I counsel patients on the vaccinations that they should...

I work as both an ER physician and a Family Physician in a clinic and something needs to be done so that I do not need to see patients in the ER for problems that could easily be handled in the less expensive clinic.  Other countries have better health plans because patients have an incentive to...

State of the art care for asthma over the past 20 years has involved giving the patient steroids to treat "late phase asthma", the mucus, edema and inflammation that happens on the INSIDE of the airways. Alvesco is different from every inhaled steroid that has come before it.  It is less likely...

MAOI's really work very well in patients in whom tricyclic and newer and safer variations of the theme (blockade of norepinephrine, serotonin, and dopamine uptake) do not.  It is about time that the focus has shifted to a safer version of MAOIs, the selective and reversible novel class of drugs...

Insurance company data is primitive and flawed. Any entity that can manage this data well in the future will be extremely profitable.

Xenoport's trial for XP13512 in restless legs syndrome (RLS) shows strongly positive 9 month data in second phase 3  trial, should be a major win in the marketplace.  RLS represent a major unmet need, for drugs with sustained efficacy and high tolerability.